 San Diego, California--Newsfile Corp. - November 22, 2022 - Skye Bioscience, Inc. OTCQB: SKYE Skye or the Company, a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announced today that it will present a corporate overview at the RHK 2022 Disruptive Growth Conference being held December 5-6, 2022, at the offices of Reed Smith in New York City. 